Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event




Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

– AACR Investor Event time change to 6:30 p.m. ET –

– 21st Annual Needham Virtual Healthcare Conference Presentation April 13th at 1:30 p.m. ET –

SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a company presentation at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th, 2022, at 1:30 p.m. ET/10:30 a.m. PT.

Alpine will host a virtual investor event on April 12th, 2022, at 6:30 p.m. ET, to coincide with the 2022 American Association for Cancer Research (AACR) Annual Meeting. The meeting will commence 30 minutes later than previously announced and will begin at 6:30 p.m. ET.

A live webcast of both events will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of each presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

Contacts

Investor Relations
Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc

206-788-4545

ir@alpineimmunesciences.com

Media Relations
Kelli Perkins

Red House

kelli@redhousecomms.com